Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This study is testing the safety and effectiveness of a new medication called brilaroxazine (RP5063) for treating schizophrenia in adults who have not been considered treatment-resistant. **You may be eligible if:** - You are between 18 and 65 years old - You have been diagnosed with schizophrenia - You have previously responded to antipsychotic medications - You are able to understand and sign an informed consent form **You may NOT be eligible if:** - You have never been treated for schizophrenia before - You have failed to respond to at least 2 different antipsychotic medications - You have a history of using clozapine - You have received electroconvulsive therapy (ECT) for schizophrenia in the past 5 years - You have another primary psychiatric diagnosis (such as major depression, bipolar disorder, or schizoaffective disorder) - You have a significant substance use disorder (other than caffeine or nicotine) in the past 6 months - You have a history of traumatic brain injury, Alzheimer's disease, or significant cognitive impairment Talk to your doctor to see if this trial is right for you.